logo
Reeves refuses to rule out autumn tax raid

Reeves refuses to rule out autumn tax raid

Yahoo2 days ago

Rachel Reeves has refused to rule out further tax rises in the Autumn as Cabinet colleagues pile pressure on the Chancellor to unleash more money for public spending.
Ms Reeves repeatedly declined to rule out raising taxes on families and businesses at an event on Thursday night as she prepares to set out Whitehall spending plans for the next three years.
'I'm not going to say that I'm not going to take any tax measures in the next four years,' she told an audience of business leaders at the Confederation of British Industry (CBI) annual dinner.
Asked four times by CBI president Rupert Soames to reassure Britons they would not be subject to higher taxes, Ms Reeves could only commit to avoiding a repeat of the record £40bn tax raid she launched last Autumn.
'I'm not going to be able to write all four years of budgets sitting here this evening,' she said.
Economists have warned that a series of spending commitments made by Sir Keir Starmer, including restoring winter fuel payments to most pensioners and speculation that the two-child cap on benefits will be lifted, will force the issue and lead to higher taxes in the Autumn.
JP Morgan has estimated that taxes may need to rise by up to £24bn to cover recent policy announcements and to compensate for the hit to growth from higher tariffs.
Pressure is also building on Ms Reeves from Labour's Left after the leak of a memo sent to the Treasury by Angela Rayner's department ahead of the Spring Statement. It detailed potential tax rises that could have avoided spending cuts to balance the budget.
Ms Reeves on Thursday insisted the economy was 'turning the corner' even as she admitted that growth was too low, leaving families 'struggling with living standards not improving'.
Bosses warned that Labour's workers' rights overhaul was set to worsen the problem. A survey by the Institute of Directors published on Friday found over seven in 10 business leaders believed the upcoming Employment Rights Bill would have a negative impact on UK economic growth.
The Chancellor insisted growth around the world had been disappointing.
'None of our countries are growing at the rate that we used to or the rate that we want to. All of us are struggling with living standards not improving and our citizens are becoming restless,' she said.
Cabinet colleagues including deputy prime minister Ms Rayner are piling pressure on the Chancellor to release more money for government departments ahead of the Spending Review on Wednesday.
Ms Reeves also hinted that the Government was preparing a package of measures to help businesses deal with higher energy costs. She signalled her three year spending review would also unleash a wave of funding for infrastructure projects, from renewables to nuclear energy.
She said: 'I know that one of the questions that we need to answer is how we're going to make energy more affordable, particularly for some of our most intensive energy-using businesses where the price differential with other countries around the world is just too acute for many to be competitive.
'And so that's a question we will answer in the industrial strategy in a few weeks.'
The cost of power for factories in Britain is now about 50pc more expensive than in Germany and France, and four times as expensive as in the US.
The commons business select committee on Friday warned that high energy prices were holding back growth and urged ministers to address the issue as part of the upcoming industrial strategy.
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

Yahoo

time29 minutes ago

  • Yahoo

Coherus BioSciences, Inc. (CHRS): A Bull Case Theory

We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Bentley Has You Covered On Tariffs—For Now
Bentley Has You Covered On Tariffs—For Now

Motor 1

timean hour ago

  • Motor 1

Bentley Has You Covered On Tariffs—For Now

If you're on the fence about which Bentley to park in your garage, it's time to jump: Bentley will honor pre-tariff pricing through the end of the month. Beyond that, what a new Bentley will cost you is anyone's guess. As the U.S. tariff situation changes with the wind, Bentley has said they'll reassess pricing in July. Bentley will continue to build and fulfill orders from US customers beyond the June window, but will halt dealer inventory moving into the country until July, keeping the vehicles in the U.K., until the situation becomes clearer. Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . For further clarification, Motor1 spoke with Bentley Chief Communications Officer Wayne Bruce during a first drive event for forthcoming models, which are under embargo. "Even now, at least until the end of June, you walk into a Bentley retailer, you order a Bentley, even if you configure a Bentley, it will be at the pre-tariff price," Bruce told Motor1. "Obviously, there are some [Bentley cars] on the ground [at pre-tariff prices] because [they were] imported before the tariffs. What we've also done currently though, is stop any retailer stock being shipped to the US until we get greater clarification on the new deal." 2026 Bentley Bentayga Speed Photo by: Bentley That means shoppers who want to walk into a Bentley showroom and drive out with a car will do so with strained inventory in the immediate future. The message from Bentley is clear: If you want a Bentley, this is the time to order, as the future's uncertain and further tariffs—or adjustments to current tariffs in place—could add costs for the customer. In response to the message, Bentley dealerships have received an influx of orders, Bruce said. "The dealers are very very happy right now." Beyond the end of June, however, we'll see if that holds. Contact the author: More Bentley News The New Bentley Bentayga Speed V-8 Outpunches the W-12 Bentley's New Bentayga Will Have 'More Power' Than the W-12 Bentley's New Hybrids Have Less Power—But Still a Lot of It Matt LeBlanc Drove This Bentley on Top Gear. You Can Buy It Bentley Made the Bentayga Even Fancier With the Atelier Edition Stellantis Wants To Take On Bentley Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store